文章核心观点 法鲁奇&法鲁奇律师事务所正调查对博尔特生物疗法公司的潜在索赔，提醒投资者9月3日2024年截止日期可争取在针对该公司的联邦证券集体诉讼中担任首席原告，鼓励在特定时期损失超5万美元的投资者联系讨论法律权利 [1][2] 分组1：律所信息 - 法鲁奇&法鲁奇是领先的全国性证券律师事务所，在纽约、宾夕法尼亚、加利福尼亚和佐治亚设有办公室，自1995年成立以来已为投资者追回数亿美元 [2] 分组2：公司违规指控 - 投诉称公司及其高管违反联邦证券法，包括BDC - 1001效果不如公司向投资者表述且不太可能达到预定成功标准、夸大产品管线临床和商业前景、面临领导过渡和大幅裁员风险、公开声明存在重大虚假和误导性 [3] 分组3：公司事件及股价影响 - 2024年5月14日博尔特宣布停止主要资产曲妥珠单抗伊莫托利莫德（BDC - 1001）进一步开发并裁员约50%，随后多位分析师下调公司股票评级，股价下跌0.49美元/股，跌幅超37.12%，5月15日收于0.83美元/股 [4] 分组4：首席原告相关 - 法院指定的首席原告是在集体寻求的救济中经济利益最大、能代表集体成员的投资者，可指导和监督诉讼，集体成员可申请担任或不作为缺席成员，是否担任不影响赔偿分享 [5] 分组5：信息征集与联系方式 - 律所鼓励任何有关博尔特行为信息的人联系，包括举报人、前员工、股东等，可访问www.faruqilaw.com/BOLT或致电法鲁奇&法鲁奇合伙人乔希·威尔逊了解更多 [1][6]

文章核心观点 - 公司BDC-1001的免疫刺激抗体偶联物(ISAC)针对肿瘤抗原HER2,但其疗效低于公司之前向投资者表述的水平,不太可能达到预定的成功标准 [1][5] - 因此,公司夸大了产品管线的临床和商业前景,这是公司维持业务模式的主要依赖 [5] - 上述情况使公司面临高风险的管理层变动和大规模裁员 [5] - 公司的公开声明在相关时期存在重大虚假和误导性 [5] 根据相关目录分别进行总结 公司概况 - 公司名称为Bolt Biotherapeutics, Inc. [1] - 公司股票代码为NASDAQ: BOLT [1] - 公司主要从事免疫刺激抗体偶联物(ISAC)的研发,其中BDC-1001针对肿瘤抗原HER2 [5] 诉讼相关 - 公司证券在2021年2月5日至2024年5月14日期间的购买者可能有权获得赔偿 [1][2] - 投资者需在2024年9月3日之前提出成为集体诉讼的代表原告 [1][3] - 原告律师事务所Rosen Law Firm在证券集体诉讼方面有丰富经验,曾获得最大规模的对中国公司的和解 [4]

Follow us for updates on LinkedIn, on X, or on Facebook. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) BDC-1001 was less eff ...

文章核心观点 - 公司BDC-1001的免疫刺激抗体偶联物(ISAC)针对人表皮生长因子受体2(HER2)抗原,效果不如公司向投资者表述的那样,很可能无法达到预定的成功标准 [1][5] - 因此,公司夸大了产品管线的临床和商业前景,这是公司维持其业务模式的主要依赖 [5] - 上述情况使公司面临高风险的管理层变动和大规模裁员 [5] - 当真实情况被披露时,投资者遭受损失 [5] 根据相关目录分别进行总结 公司概况 - 公司名称为Bolt Biotherapeutics, Inc. [1] - 公司股票代码为NASDAQ: BOLT [1] - 公司主要从事免疫刺激抗体偶联物(ISAC)的研发,其中BDC-1001针对HER2抗原 [5] 诉讼情况 - 公司在2021年2月5日至2024年5月14日期间(包括两个日期)的证券交易遭到集体诉讼 [1] - 原告要求在2024年9月3日之前指定首席原告代表集体利益进行诉讼 [1][3] - 原告律师事务所为Rosen Law Firm,声称拥有丰富的证券集体诉讼经验 [4] 指控内容 - 公司对BDC-1001的临床和商业前景做出了虚假或误导性陈述 [5] - 公司夸大了产品管线的前景,这是公司维持业务模式的主要依赖 [5] - 上述情况使公司面临高风险的管理层变动和大规模裁员 [5] - 当真实情况被披露时,投资者遭受损失 [5]

If you are a shareholder who suffered a loss, click here to participate. LOS ANGELES, July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ: BOLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. CONTACT: The Schall Law Firm Brian Schall, Esq. ...

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The complaint alleges that on May 14, 2024, Bolt issued a press release announcing that the Company would cease further development of BDC-1001 and focus resources on BDC-3042 and BDC-4182 upon determining that BDC-1001 failed to meet its pre-defined success criteria, that the Company's Chief Executive Officer Randall C. Schatzman and Chief Medical Officer Edith Perez would be moved into advisory roles ...

SO WHAT: If you purchased Bolt securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) BDC-1001, Bolt's immune-stimulating antibody conjugate ("ISAC") designed to target a tumor antigen known as human epidermal growth factor receptor 2 ("HER2") that is often found in cance ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bolt To Contact Him Directly To Discuss Their Options Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP) On May 14, 2024, Bolt announced in a press release that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)," Bolt's lead asset, "and reduce workforce by approximately 50%." Following Bolt's announcement, multiple analysts d ...

NEW YORK, July 15, 2024 /PRNewswire/ -- What to do next: To join the Bolt class action, go to https://rosenlegal.com/submit-form/?case_id=26946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 3, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigati ...

NEW YORK, July 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SeaStar Medical Holding Corporation (NASDAQ: ICU) and Bolt Biotherapeutics (NASDAQ: BOLT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Class Period: October 31, 2022 - March 26 ...